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Abstract: 
Cutaneous leishmaniasis (CL) is a neglected tropical disease that causes prominent skin 
scaring. No water soluble, non-toxic, short course and low cost treatment exists. We 
developed a new water soluble amphotericin B-polymethacrylic acid (AmB-PMA) using 
established and scalable chemistries. AmB-PMA was stable for 9 months during storage. 
In vitro, it was effective against Leishmania spp. promastigotes and amastigote infected 
macrophages. It was also less toxic and more effective than deoxycholate-AmB, and 
similar to liposomal AmB. Its in vivo activity was determined in both early and 
established CL lesion models of Leishmania major infection in genetically susceptible 
non-healing BALB/c mice. Intradermal AmB-PMA at a total dose of 18 mg of AmB/kg 
body weight led to rapid parasite killing and lesion healing.  No toxicity was seen. No 
parasite relapse occurred after 80 days follow-up. Histological studies confirmed rapid 
parasite clearance from macrophages followed by accelerated fibroblast mediated tissue 
repair, regeneration and cure of the infection. Quantitative mRNA studies of the CL 
lesions showed that accelerated healing was associated with increased Tumor Necrosis 
Factor-α and Interferon-γ, and reduced Interleukin-10. These results suggest that a cost-
effective AmB-PMA could be used to pharmacologically treat and immuno-
therapeutically accelerate the healing of CL lesions. 
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1. Introduction:
Cutaneous leishmaniasis (CL) is a global vector borne neglected parasitic disease with 
increasing incidence. Most cutaneous disease is caused by Leishmania major, L. tropica, 
L. braziliensis and L. panamensis. It typically occurs as a single cutaneous lesion on 
exposed body parts (face and upper limb) and varies in size from nodules to large ulcers. 
It leads to disfiguring scars. This means that early and effective treatment is important for 
a good clinical outcome. To date, no effective vaccine exists, and the current drug 
formulary is limited by toxicity, increasing resistance, and costly long treatment 
regimens. The ideal low cost treatment should kill parasites rapidly and accelerate tissue 
repair by combining pharmacological with immuno-therapeutic approaches. 
To date, there is no water soluble, short-term and highly effective treatment that is cost 
effective and also free of side-effects[1,2]. In this context, it is important to note that, in 
both animal models and man:- (i) water soluble deoxycholate-AmB is ineffective; (ii) 
water soluble high dose intravenous liposomal AmB leads only to the temporary 
resolution of CL lesions[3-7]. 
Leishmania sp. are obligate intracellular protozoa that infect, multiply and persist in 
macrophage endosomes. The organism has evolved to survive in the harsh environment 
of the phagolysosome, an organelle in which pathogens are usually destroyed. 
Amphotericin B is a polyene antibiotic produced by Streptomyces sp.. It is not water 
soluble and therefore has to be dissolved in neat DMSO. Parasite resistance to 
*
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amphotericin B (AmB) has not occurred after 50 years of clinical use. AmB binds 
selectively to parasite membrane ergosterol and, to a lesser extent, human cholesterol. 
There is still a lack of detailed understanding of the relationship between its physico-
chemical properties, pharmacokinetics and therapeutic activity[8-14]. The amphiphilic 
and ampholytic properties of AmB lead to the formation of aggregates in water which are 
toxic in man[8-12]. However, all existing water and lipid based formulations of AmB are 
ineffective at curing CL in controlled animal models[3-5]; (i) in the non-healing BALB/c 
mouse model of L. major, high dose intravenous LAmB (25 - 50 mg of AmB/kg for 6 - 
12 days) led only to the temporary resolution of CL lesions; (ii) deoxycholate-AmB was 
ineffective; (iii) nanodisk associated AmB, when given intraperitoneally (5 mg of 
Amb/kg) over 21 days, led to the slow healing of CL lesions over 140 - 250 days. 
There is also evidence to suggest that strengthening the host’s immune responses with 
immuno-therapy could provide a therapeutically useful addition to the pharmacological 
activity of AmB[15]. This is because the clinical manifestations of leishmaniasis are a 
consequence of the balance between parasite defence mechanisms and host microbicidal 
and immunological responses. A T-helper type 1 (Th1) immune response that increases 
interferon (IFN) -γ production promotes parasite killing while a Th2 response enables 
parasite persistence[16-22]. 
We chose to work with polymethacrylic acid (PMA) because recent years have 
witnessed:- (i) the advent of PMA hydrogel capsules that are safe in animals: (ii) their 
development into a mature biomedical platform[23]. Studies have shown that under 
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carefully defined conditions of stoichiometry, relative molecular mass, pH, anionic 
strength and temperature, mixtures of oppositely charged polyelectrolytes can form 
discrete, stable and water soluble macromolecules via hydrogen bonded self 
assembly[24-26]. This relies upon the self assembling ability of polycarboxylic acids; the 
hydrogen bonds formed act co-operatively to create strong oligomeric structures that 
have a polyanionic coat in water. In the case of PMA, there is the added advantage that 
its hydrogel swelling behaviour is pH dependent, and that it forms structures with 
properties that resemble biological tissues[27,28]. At alkaline pH (e.g., pH 8), its 
carboxylic acid groups are ionized and they repel each other; this means that the PMA 
hydrogel swells and small molecule drugs can be trapped within its matrix. However, at 
acid pH (e.g., pH 5), the carboxylic acid groups are not ionized and the PMA hydrogel 
collapses; the small molecule drug is released. This makes these pH responsive molecules 
with rapid and reversible switching between well defined size based conformations into 
useful candidates for miniaturized drug delivery for certain tissue micro-environments. In 
addition, anionic linear polymers with a MWt of 15 - 25 kDa preferentially accumulate in 
the endosomes of tissue macrophages in both animals and man, and have been shown to 
be non-toxic[29-33]. 
These physical properties of PMA and its widespread pharmaceutical use over many 
years[26,34] led us to investigate whether a new, low cost, heat stable and water soluble 
AmB based drug could be made for CL using established, scalable and low cost 
chemistries [35]. We now report our detailed results in both an early CL lesion and an 
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established CL lesion non-healing BALB/c mouse model following infection with L. 
major organisms. 
2. Materials and Methods:
2.1. Ethics statement: 
All procedures involving animals were approved by and performed in accordance with 
the United Kingdom Government (Home Office) licence (PPL70/6712) and the 
requirements and regulations laid down by the ethical review committee of Imperial 
College London. Animals were kept in cages and provided with food and water ad 
libitum. The 3Rs of replacement, reduction and refinement were adhered to. 
2.2. Chemical synthesis & analytical characterisation: 
 A fully hydrolysed polymethacrylic acid sodium salt (PMA; Mp 18.5 kDa, Mw 18.6 kDa, 
pKa 7.3, Sigma {i.e., the gas phase chromatography standard used for polymer 
characterisation}) was treated with activated charcoal to remove lipopolysaccharide. 
Endotoxin free AmB (amine pKa 10.0) and glassware, and water for injection were used 
to make the AmB-PMA. AmB is insoluble in water. It is soluble in neat DMSO. PMA 
was dissolved in water at 5 mg/ml. The water soluble PMA was then added to the AmB 
dissolved in DMSO (5 mg/ml; i.e., soluble and monomeric AmB). Sodium hydroxide (1 
N) followed by water were added slowly and the mixture stirred at pH 9.2 for 1 h at 20ºC.
Under these conditions, the ampholytic character of AmB enabled its hydrogen bond 
mediated self assembly with  ionized carboxylic acids in the swollen PMA hydrogel’s 
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matrix. In contrast, the simple mixing of AmB with PMA led only to the formation of an 
insoluble mass that could not be drawn up and administered by injection. The solution 
was dialysed against water to remove DMSO and free AmB, and then freeze dried. The 
AmB-PMA’s endotoxin content was <0.06 EU units/ml; i.e., the EU standard for water 
for injection. It was stored in the dark under argon at 4ºC. The percentage loading of 
AmB was determined in 50% methanol by UV spectroscopy at 409 nM, and the relative 
distribution of the different forms of AmB determined in water by UV spectroscopy from 
300 to 450 nm[11,36]. 
2.3. In vitro biological evaluation: 
The haemolytic activity of PMA and AmB-PMA was determined by the degree of 
erythrocyte cell membrane lysis of a 2% v/v solution of washed human erythrocytes at 1 
h[9]. The compounds were dissolved in serum free RPMI media. A 1% (v/v) solution of 
the detergent Triton X-100 was used as the 100% cell lysis positive control. After 
incubating the compound with the cells in triplicate for 1 h, the tissue culture plate was 
centrifuged and the supernatant’s optical density determined at 409 nm. 
The cellular toxicity of PMA and AmB-PMA was determined by culturing each molecule 
with the macrophage cell line U937, and with mouse bone marrow derived macrophages, 
and with human monocyte derived macrophages.  Cells were suspended at 1 x 10
6
/ml and
serial dilutions of the compound (0 - 500 µg/ml of PMA and 0 - 500 µg/ml of AmB for 
AmB-PMA) added in triplicate. A 2% (v/v) solution of Triton X-100 was used as the 
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100% cell lysis positive control. The plates were incubated at 37°C, 5% CO2 for 3 days 
after which MTT was added and cell viability determined. 
The immuno-modulatory properties of PMA and AmB-PMA were determined by 
culturing each molecule with the macrophage cell line U937, and with human monocyte 
derived macrophages. Cells in RPMI/10% FCS were plated at 1 x 10
6
/ml and left to
adhere overnight at 37ºC, 5%, CO2. Compounds were then added in triplicate and in 
serial dilution (0 - 500 µg/ml of PMA and 0 - 500 µg/ml of AmB for AmB-PMA) for 1 h 
and the cells cultured for 3 h. The plate was then centrifuged at 1,800 rpm for 5 min and 
the supernatant removed. For each assay, the negative control was cells cultured without 
compound and the positive control was 25 ng/ml of highly purified LPS because it 
induced a maximal chemokine and cytokine response[37]. 
The cells were lysed with Trisol (Tri Reagent, Sigma Aldrich) and the cell pellet 
harvested. RNA was isolated using Max Tract tubes (Qiagen) and the phenol/chloroform 
method for precipitating RNA. It was then dissolved in RNase-free water ready for 
reverse transcription. Quantitative real time RT-PCR for MIP-1β (CCL4), TNF-α, IL-2, 
IL-4, IL-6, IL-10, IL-12p40, IFN-γ and iNOS mRNA was performed as previously 
described[37] (and see also the additional details provided below). The 3 h time point for 
harvesting mRNA was chosen because it was optimal for detecting the cytokines listed. 
The in vitro anti-leishmanial activity of PMA and AmB-PMA was determined against L. 
major and L. donovani stationary phase promastigotes using an MTT assay[4]. One 
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hundred thousand promastigotes in supplemented SD media were seeded per well and the 
compound added in triplicate. The plates were incubated in a humidified chamber at 
26°C, 5 % CO2 for 24 h. A 2% (v/v) solution of Triton X-100 was used as the 100% cell 
lysis positive control. MTT was added, the plate incubated for 24 h, and then centrifuged 
at 1,600 rpm for 5 min. The supernatant was removed, DMSO added, and promastigote 
viability determined at an optical density of 570 nm. 
The in vitro anti-leishmanial activity of PMA and AmB-PMA was determined using 
mouse bone marrow derived macrophages[4]. Cells were plated at 5 x 10
5
/ml onto
chamber slides (Lab-Tek) and left to adhere for 24 h. Healthy dividing L. major 
promastigotes were added at a multiplicity of infection (MOI) of 5:1 to both resting 
macrophages, and to activated macrophages which had been treated with both 
recombinant mouse IL-4 (20 Units/ml, PeproTech, UK) and recombinant mouse IL-10 
(10 U/ml, PeproTech, UK). The compound was then added and the cells cultured at 
37°C, 10% CO2 for 3 days. The optimum end point for the experiment was determined by 
collecting cells at various time points and staining them with Giemsa May Grunwald. The 
average intracellular parasite load was determined by oil immersion microscopy of 200 
stained macrophages and performed in duplicate. The infection index was expressed as 
the average number of intracellular parasites per 100 infected macrophages. 
The in vitro anti-leishmanial activity of PMA and AmB-PMA was also determined 
against both L. donovani amastigote infected mouse bone marrow derived macrophages 
and L. donovani amastigote infected human monocyte derived macrophages[4]. Cells 
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were plated at 7.5 x 10
5
/ml onto chamber slides (Lab-Tek) and left to adhere for 24 h.
Healthy dividing amastigote cultures were prepared, the amastigotes pelleted, and then 
washed with PBS before resuspending them in serum free media; Leishmania spp. are 
sensitive to complement mediated lysis. Amastigotes were then added to the 
macrophages at a MOI of 5:1 and the cells cultured at 37°C, 10 % CO2 for 3 days. 
Infection was confirmed at day 1 by fixing some cells, staining with Giemsa May 
Grunwald, and microscopically counting the number of intracellular amastigotes. The 
media was then aspirated and the macrophages washed with PBS. The compound was 
dissolved in culture media, added to the cells, and incubated for 3 days. The macrophages 
were washed to remove any extracellular amastigotes and the slides dried, fixed with 
methanol, and stained with Giemsa May Grunwald. The average intracellular parasite 
load was determined by oil-immersion microscopy of 200 Giemsa stained macrophages 
and performed in duplicate. The infection index was expressed as the average number of 
intracellular parasites per 100 infected macrophages. 
2.4. In vivo biological evaluation: 
Animal studies were performed under UK Home Office and Imperial College licences for 
animal experimentation. The in vivo efficacy of the PMA and AmB-PMA was 
determined in the genetically susceptible BALB/c mouse model of CL[38].  In this non-
healing mouse model, an inability to activate macrophages and a poor cell mediated 
immune response results in chronic ulceration at the site of cutaneous parasite 
inoculation[39,40].  Disease was induced by subcutaneous injection into the hind footpad 
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of 2 x 10
6
 stationary phase L. major LV 39 (MRHO/SU/59/P-strain) promastigotes that 
had been cultured directly from lesion amastigotes to ensure their virulence. The parasite 
load in footpad lesions from killed mice was determined by spraying the footpad with 70 
% ethanol followed by its sterile removal. The skin was dissected away and the footpad 
cut into smaller pieces before homogenising it through a metal sieve. Single cell 
suspensions were prepared using a pestle in 2 ml of PBS. A 10% dilution in PBS was 
then made before adding 10 µl to a calibrated Neubauer haemocytometer and counting 
the number of L. major parasites present[41]. 
 
AmB-PMA was administered with a very fine 29G needle. In the early lesion model, 3 
intradermal footpad injections were given on days 7, 14 and 21 post infection. In each 
injection of 50 µl, the concentration of AmB was 2.7 mg/ml making a total of 400 µg of 
AmB/mouse (i.e., 18 mg of AmB/kg body weight). In the established lesion model, 
AmB-PMA was started at day 21 following confirmation of an established infection in a 
subgroup of 4 footpads; i.e., >2 x 10
6
 amastigotes/footpad[41,42].  Three intradermal 
footpad injections were given over the course of one week on days 21, 25 and 28 post-
infection. In each injection of 50 µl, the concentration of AmB was 2.7 mg/ml making a 
total dose of 400 µg of AmB/mouse (i.e., 18 mg of AmB/kg body weight). Body weight 
and lesion size were monitored regularly until day 80 by determining the increase in 
footpad thickness of the infected footpad as compared to the control contralateral footpad 
using a dial gauge calliper (Kröplin Schnelltaster, Schlüchtern, Germany). In both the 
early lesion model and in the established lesion model, at least three independent 
experiments were performed. Control mice were culled when their footpad lesion reached 
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4 mm in diameter and were ulcerated, and in accordance with the terms of our animal 
licence. Healing and cure were defined as the disappearance of induration and complete 
re-epithelialization of the footpad with no lesion relapse at day 80 post infection. 
2.5. Delayed type hypersensitivity (DTH) response to reinfection: 
The delayed type hypersensitivity (DTH) response to reinfection after a therapeutic 
response to AmB-PMA treatment was also evaluated. Sixty days after the primary 
infection, 12 BALB/c mice with healed lesions were challenged with 2 x 10
6
 stationary
phase L. major (LV 39) promastigotes in the uninfected contralateral footpad. Mice with 
healed lesions by day 35 were compared with mice with an unhealed primary infection at 
day 50. Both footpads were monitored. The change in size of each footpad was recorded 
as the increase in footpad thickness after its inoculation relative to the size of the same 
footpad just before its inoculation. Daily measurements were made using a dial gauge 
calliper (Kröplin Schnelltaster, Schlüchtern, Germany) for 7 days. 
2.6. Animal studies with free AmB, deoxycholate-AmB or liposomal-AmB: 
We were restricted in the additional animal model based studies that could be performed 
using free AmB, Fungizone (Squibb; i.e., deoxycholate-AmB) or AmBisome (Gilead; 
i.e., liposomal-AmB) for the following toxicity related reasons. Firstly, free AmB is not
absorbed through the skin, is insoluble in water, and will only dissolve in an organic 
solvent like neat DMSO. Although DMSO can be used on the skin at a 10% 
concentration, we found that free AmB was insoluble in 10% AmB . Secondly, 
Fungizone and AmBisome have been shown to be biologically ineffective in published 
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animal model based studies of CL caused by L. major, irrespective of the route of drug 
administration[3-5]. Thirdly, Fungizone is made up of 33% AmB and 66% deoxycholic 
acid, which is a detergent. When injected at a concentration of only 2.5% into 
subcutaneous tissues, deoxycholic acid causes intense pain, swelling, acute inflammatory 
lympho-mononuclear infiltration, adipocyte apoptosis with fat necrosis, intense 
phagocytosis of fat cells by subcutaneous tissue macrophages, and necrosis of small 
blood vessels[43,44]. Fourthly, the product monograph for Ambisome states that it can 
cause significant tissue inflammation when injected subcutaneously in both rats and man 
(i.e., accidental drug extravasation from an intravenous infusion). Fifthly, the extensive 
studies of liposomes by Oussoren et al. have shown that both the route of administration 
and the composition of liposomes are important determinants of their toxicity[45]. For 
example, liposomes given by intramuscular injection have a faster and more complete 
clearance of the drug from the injection site (and therefore less local toxicity) than those 
given by subcutaneous injection. Kadir et al. found that intramuscular injections of 
liposomes led to macrophage and fat cell infiltration which, in time, came to be replaced 
by loose connective tissue[46]. This has meant that, in recent years, liposome based drug 
delivery to the skin and subcutaneous tissue has not been proactively developed by the 
pharmaceutical industry as a useful new drug delivery method for liposomes. For all of 
these toxicity related reasons, we were unable to perform comparator animal studies with 
either free AmB or with the licensed products Fungizone and AmBisome. 
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2.7. Quantitative real time mRNA RT-PCR: 
Trisol (Tri Reagent, Sigma Aldrich) was used to lyse the cells and the cell pellet 
harvested for RNA extraction. RNA was isolated using Max Tract tubes (Qiagen) and the 
phenol/chloroform method for precipitating RNA. It was then dissolved in RNase-free 
water and 400 ng reverse transcribed with a Qiagen RT kit. Quantitative RT-PCR was 
performed at least twice and in triplicate on each sample using Sybr Green Jumpstart 
PCR mix (Sigma) and a Corbett Rotorgene 3000. Quantification was performed using a 
multi-gene plasmid that contained cloned gene sequences for chemokines and cytokines 
and the reference gene HPRT[37,47]. Standards were diluted in the range 20 - 2 x 10
7 
copies. The PCR assays had good linearity (mean r
2
 = 0.997) for all standard curves and a
mean coefficient of variation of 8%. Results were determined as the absolute mRNA 
copies/10
5 
HPRT copies. Using this assay, 3-fold differences in mRNA copy number
could be reliably and reproducibly determined. 
The primer sequences used were:- 
HPRT forward (f)GTAATGATCCAGTCAACGGGGGAC 
HPRT reverse (r)GCAAGCTTGCAACCTTAACCA; 
MIP-1β (CCL4) (f)CCTCTCTCTCCTCTTGCTCGT, 
(r)GCAAAGACTGCTGGTCTCATAG; 
TNF-α (f)CACCACGCCTCTGTGTCTACTG, (r)TGAGAAGATGATCTGACTGTGA; 
IL-2 (f)CTTCAGTGTCTAGAAGAAGAACT, 
(r)AATGTTGTTTCAGATCCCTTTAGTT; 
IL-4 (f)TCAACCCCCAGCTAGTTGTC, (r)TGTTCTTCGTTGCTGTGAGG; 
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IL-6 (f)ACCGCTATGAAGTTCCTCTCTG, (r)AATTAAGCCTGCGAGACTTGTGAA; 
IL-10 (f)GGTTGCCAAGCCTTATCGGA, (r)ACCTGCTCCACTGCCTTGCT; 
IL12 p40 (f)CCTGAAGTGTGAAGCACCAA, (r)AGTCCCTTTGGTCCAGTGTG; 
IFN-γ (f)TCAAGTTCAAGTGGCATAGATGTGG, (r)TGGCTCTGCAGGTTTTCATG; 
iNOS (f)GTTCTCAGCCCAACAATACAAGA, (r)GTGGACG GGTCGATGTCAC. 
2.8. Histological studies: 
Tissues were fixed with 10% formalin saline for 24 h and embedded in paraffin wax. One 
micron thick sections were cut from the paraffin blocks and stained with haematoxylin 
and eosin (H & E) and Periodic acid Schiff (PAS) stains. 
2.9. Data analysis: 
Data analysis was performed using Graphpad Prism 4 software. Results are given as the 
mean ± sem. p values were determined using a Mann-Whitney test. 
3. Results:
3.1. Analytical characterisation of AmB-PMA: 
Under the alkaline synthesis conditions used, the ampholytic (i.e., able to react as either 
an acid or base) character of AmB enabled its amine (pKa 10.0) to complex with the 
ionized carboxylic acids in the swollen PMA hydrogel (pKa 7.3) via co-operative 
hydrogen bonds. Initial structure-function studies established that an AmB loading of 28 
± 2 % was optimum for ensuring the long-term stability (i.e., 9 m) of AmB-PMA at 
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physiological pH (i.e., 7.3); free AmB has a shelf-life of 12 months[47,48]. The median 
diameter of AmB-PMA was 61 nm by dynamic light scattering as compared to 53 nm for 
deoxycholate-AmB (Fungizone, Squibb) and 78 nm for liposomal-AmB (LAmB, 
AmBisome, Gilead). The circular dichroism (CD) spectra from 250 to 450 nm of AmB-
PMA was similar to deoxycholate-AmB[47,48].  The UV spectroscopic distribution of 
AmB in AmB-PMA was also similar to that in deoxycholate-AmB and liposomal-AmB 
(Figure 1a). 
The AmB-PMA dissolved easily at 4 mg/ml in water for injection at pH 7.3 to give a 
clear, yellow and water soluble solution. It remained in solution after centrifugation at 
30,000 rpm for 30 min. However, when the solution’s pH was decreased from 6.6 to 6.3, 
the AmB was released from PMA as confirmed by UV spectroscopy, and the solution 
became turbid because of the presence of free and water insoluble AmB. The free AmB 
could now be pelleted by centrifugation at 1,800 rpm for 10 min (Figure 1b). The same 
result was obtained when this experiment was repeated by dissolving the AmB-PMA in 
RPMI media containing 10% serum. 
3.2. In vitro activity and toxicity of PMA and AmB-PMA: 
PMA was not toxic to erythrocytes or macrophages at 2 mg/ml after 24 h in an MTT 
assay.  It was also not toxic to either cell type at 500 µg/ml after 3 days. PMA had no 
intrinsic anti-leishmania activity. Endotoxin free (i.e., <0.06 EU/ml) PMA did not 
stimulate Macrophage Inflammatory Protein (MIP) -1β (CCL4), TNF-α, IL-2, IL-4, IL-6, 
IL-10, IL-12p40, IFN-γ or iNOS synthesis in macrophages up to 2 mg/ml. 
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Erythrocyte lysis by endotoxin free AmB-PMA (at 30 µg of AmB/ml) was 5 ± 1 % 
compared to 100 ± 5 % for deoxycholate-AmB, and 4 ± 1 % for LAmB after 1 h (Figure 
2). No toxicity was seen in macrophages with AmB-PMA at 400 μg of AmB/ml after 3 
days. In stability studies, lyophilised AmB-PMA powder was chemically stable (as 
determined by its loading of AmB, UV spectroscopic distribution, pH responsiveness and 
CD spectra) (see Supplementary Figure 1) and bioactive (as determined by erythrocyte 
lysis, macrophage toxicity and anti-leishmania activity) after 9 months storage at 
4ºC[47,48]. 
The 50% lethal dose (LD50) of endotoxin free AmB-PMA for L. major promastigotes was 
0.3 ± 0.1 μg of AmB/ml and for L. donovani promastigotes was 0.12 ± 0.1 μg of 
AmB/ml. For L. donovani amastigotes in macrophages, the LD50 of AmB-PMA was 0.07 
± 0.1 μg of AmB/ml compared to 0.22 ± 0.1 μg of AmB/ml for deoxycholate-AmB, and 
0.11 ± 0.1 μg of AmB/ml for liposomal AmB (Figure 3). 
In the human monocyte derived macrophage based model of chemokine and cytokine 
expression that we have previously described in detail, the maximal pro-inflammatory 
response occurred with 25 ng/ml of ultrapure Salmonella minnesota lipopolysaccharide 
(LPS)[37]. In the macrophage cell line U937, neither PMA (12.5 - 200 µg/ml) nor AmB-
PMA (12.5 - 200 µg of AmB/ml in the AmB-PMA) had any effect on MIP-1β, TNF-α, 
IL-10 or IFN-γ.  The maximal TNF-α response that could be induced in human monocyte 
derived macrophages with endotoxin free AmB-PMA (50 µg of AmB/ml) was 30 ± 7% 
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of the maximal response seen with LPS (Figure 4). This contrasted with 107 ± 22% for 
deoxycholate-AmB. Liposomal AmB did not stimulate a TNF-α response. In the case of 
IFN-γ, the maximal response with endotoxin free AmB-PMA was 88 ± 13% of the 
maximal response seen with LPS, and 98 ± 12% for deoxycholate-AmB (Figure 4). 
Liposomal AmB did not stimulate an IFN-γ response. Finally, endotoxin free AmB-PMA 
did not stimulate IL-10, MIP -1β, IL-2, IL-4, IL-6, IL-12p40 or iNOS. These in vitro 
results showed that AmB-PMA was stable, non-toxic, efficiently killed Leishmania 
amastigotes in macrophages, and had immuno-modulatory properties. 
3.3. AmB-PMA in BALB/c mice with CL lesions: 
The in vivo activity of AmB-PMA was determined in both early and established non-
healing CL footpad lesions in genetically susceptible BALB/c mice infected with L. 
major promastigotes. In this non-healing model of CL, an inability to activate 
macrophages and a poor cell mediated immune response results in parasite persistence 
and a sustained neurophil response that leads to chronic tissue ulceration. This is because 
the parasites modify their local cytokine environment such that the chemoattractants 
required for effector immune cell recruitment do not accumulate[49,50,51]. This 
immunological profile is similar in the subcutaneous (footpad) and intradermal (ear) 
models of L. major infection in BALB/c mice[52]. 
In control experiments, endotoxin free PMA reconstituted in water for injection was not 
toxic to mice, and had no effect on either parasite count or cytokine levels[47,48]. In 
preliminary dose-response studies with AmB-PMA in the early lesion mouse model, 
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several treatment schedules and doses were evaluated[47,48]. These studies showed that:- 
(i) a total dose of 150 µg of AmB/mouse led to a 95% reduction in parasite load but only 
a 75% reduction in lesion size; (ii) a total dose of 250 µg of AmB/mouse led to a 95% 
reduction in parasite load and a 95% reduction in lesion size. These observations led us to 
perform detailed studies with a total dose of 400 µg of AmB/mouse (i.e., 18 mg of 
AmB/kg body weight) administered as three intradermal footpad injections of 50 µl each. 
3.4. AmB-PMA in BALB/c mice – early CL lesion model: 
In the early lesion model, 24 mice were treated over a 3 week period on days 7, 14 and 21 
post-infection. Six control mice received water injections of 50 µl each. Eighteen treated 
and 6 control mice were culled at day 35 (Figure 5a & Supplementary Figure 2a). The 
remaining 6 treated mice continued to be monitored twice weekly until day 80 and were 
then culled. 
3.5. AmB-PMA in BALB/c mice – established CL lesion model: 
In the established and shortened one week treatment lesion model, the presence of an 
established infection was first confirmed by harvesting 4 control mice for parasite load 
determination and histological studies. Sixteen mice were then treated with AmB-PMA 
over a one week period on days 21, 25 and 28 post-infection. Six control mice received 
water injections of 50 µl each; all were culled by day 52 because their footpad lesions 
reached the maximum size allowed by our animal license (Figure 5b). The 16 treated 
mice were monitored twice weekly until day 80 and then culled (Supplementary Figure 
2b). 
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In these CL lesion models, AmB-PMA led to efficient parasite killing and resolution of 
non-healing cutaneous lesions in L. major infected BALB/c mice. The parasite number 
fell by >3 log10 as determined by both ex-vivo counting (Figure 6) and detailed 
histological studies performed at regular time points (Figure 8). In addition, there was no 
relapse of CL lesions during long-term follow up from day 35 to day 80 in the established 
lesion model (Figure 5b). 
3.6. AmB-PMA in BALB/c mice – toxicity studies: 
There was no clinical (i.e., weight and general well being as assessed by feeding and 
drinking behaviour, and the state of the animal’s fur), haematological (i.e., haemoglobin, 
white cell count, platelet count) clotting (i.e., prothrombin time, kaolin partial 
thromboplastin time, thrombin time), renal biochemistry (i.e., plasma sodium, potassium, 
bicarbonate, urea, creatinine) or hepatic biochemistry (i.e., plasma aspartate 
transaminase, alkaline phosphatise, albumin, calcium, phosphate) evidence of AmB-PMA 
toxicity. These in vivo studies showed that AmB-PMA led to the rapid control of parasite 
load in genetically susceptible BALB/c mice with non-healing lesions, and to the 
accelerated healing and cure of both early and established CL lesions. 
3.7. Delayed type hypersensitivity (DTH) response to reinfection: 
Animals cured of CL with AmB-PMA in one footpad were then challenged with 
infectious parasites in the contralateral footpad. Sixty days after the primary infection, 12 
BALB/c mice with healed primary lesions were challenged with 2 x 10
6
 stationary phase
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L. major (LV 39) promastigotes on three separate occasions. Mice with healed lesions by 
day 35 were compared with mice with an unhealed primary infection at day 50. A 
delayed type hypersensitivity (DTH) response was only seen in those mice whose 
primary footpad lesion had healed by day 35 (Figure 7). This result is interesting because 
it suggests that Leishmania specific T-cells were being recalled to the challenge site. The 
observation is notable because inoculation with live parasites is the only intervention that 
has previously been shown to provide effective immunity; it enabled the recall of an early 
and sustained IFN-γ response[53,54]. 
3.8. Histopathological studies: 
Multiple, well established and histologically circumscribed areas of infection with central 
foci of necrosis were present in CL lesions by day 7 after parasite inoculation. 
Neutrophils were present in established lesions (Figure 8a & b). Macrophages containing 
L. major amastigotes were present in untreated established lesions, with plasma cells at 
the lesion’s periphery (Figure 8c). They did not organise into granulomas. In AmB-PMA 
treated mice, amastigotes disappeared rapidly from the endosomes of macrophages 
(Figure 8d & e), and the acute inflammatory infiltrate started to resolve after the first dose 
of AmB-PMA. By day 80, organising fibroblasts were the predominant cell type present 
with only occasional macrophages seen. No amastigotes were present (Figure 8f)[55]. 
The macroscopic appearance of the untreated footpad lesion on day 35 and that of the 
treated and healed footpad lesion on day 80 is shown in Supplementary Figure 2. 
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3.9. Quantitative mRNA real time RT-PCR studies: 
The highest cytokine mRNA copy number and the largest changes with AmB-PMA 
treatment were seen at the site of parasite growth and lesion development in the 
inoculated footpad. TNF-α and IFN-γ were both elevated in AmB-PMA treated footpad 
lesions at the first point sampled (day 14). TNF-α then fell to low levels but IFN-γ 
remained elevated until the cutaneous lesion had healed (p<0.001) (Figures 9a & b). This 
cytokine increase was associated with a sustained increase in footpad iNOS during the 
lesion’s healing phase (p<0.001) (Figure 10). AmB-PMA also led to a fall in footpad IL-
10 to control lymph node levels (p<0.001) (Figure 9c). There was no significant change 
in MIP-1β (CCL4) (Figure 9d). AmB-PMA also had no effect on footpad IL-2, IL-4, IL-6 
or IL-12p40. 
In the lesion’s draining lymph nodes, chemokine and cytokine levels were much lower 
than those found at the site of footpad infection. There was a modest increase in lymph 
node TNF-α as footpad TNF-α fell (Figure 9a). In contrast, draining lymph node IFN-γ, 
IL-10 and MIP-1β (CCL4) did not show a substantial change (Figures 9b - d).  iNOS 
showed a modest increase during the latter stages of lesion healing. There were no 
differences in spleen TNF-α, IFN-γ, IL-10 and IL-12p40 between AmB-PMA treated and 
control animals. 
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4. Discussion:
Our results show that established, scalable and low cost synthetic chemistries can be used 
to make a water soluble AmB-PMA drug that is both safe and stable. In an established 
and non-healing mouse model of CL lesions, a one week course of 3 intradermal 
injections led to the rapid pharmacological killing of parasites followed by accelerated 
healing and cure of the lesion. The accelerated healing was associated with increased 
TNF-α, IFN-γ and iNOS in the lesions, and reduced IL-10. In mice with an AmB-PMA 
healed primary infection that were rechallenged with infectious parasites, a DTH 
response was seen. Taken together, these results suggest, for the first time, that it may be 
possible to combine the anti-parasite pharmacology of AmB with host immune responses 
to enhance the cost-effective healing and cure of CL lesions. 
Although several studies over many years have suggested that some macromolecules can 
have immuno-modulatory properties[55-59], we found that this was not the case for 18.5 
kDa PMA. Macrophages cultured with PMA over a wide concentration range (0 – 2 
mg/ml ) did not alter their homeostatic chemokine or cytokine production (Figure 4), and 
no immuno-modulatory activity was seen when PMA was administered to mice by a 
variety of routes[47,48]. This was an important new finding because other 
macromolecules with immuno-modulatory properties have proved difficult to progress as 
pharmaceutical drugs; this reflects their lack of homogeneity, irrespective of whether they 
are derived from natural or synthetic chemistry sources. 
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Cohen et al. have recently suggested that an ideal drug delivery system should have a 
diameter of 25 - 100 nm[60]; in our case the AmB-PMA has a diameter of 61 nm.  
Another of our aims was to safely deliver AmB to parasitized macrophage endosomes in 
established CL lesions. This was made possible by the different pKa values of PMA and 
AmB. At physiological pH (i.e., 7.3), the degree of ionization of the carboxylic acids of 
PMA is small (pKa 7.3), and of the amine of AmB is large (pKa 10.0). This means that 
during the alkaline synthesis of AmB-PMA (i.e., when the solution pH >PMA’s pKa), the 
ionized carboxylic acids of PMA led to the formation of a hydrogel based matrix within 
which a defined concentration of AmB could be trapped and retained via hydrogen 
bonded self assembly.  This enabled the non-toxic transport of AmB through tissues and 
into the cytoplasm. However, in the acidic micro-environment of the endosomal-
lysosomal compartment (pH 5 - 5.5) in which the parasite survives and persists, the 
carboxylic acids were no longer ionized, the hydrogen bonds disappeared, and the 
hydrogel’s matrix collapsed. As a result, AmB was released. This transition of PMA from 
its swollen to its collapsed state occurred over the narrow pH range of 6.5 - 6.7. 
Endosomal AmB disrupted the amastigote’s membrane integrity, exposed parasite 
cytoplasm to a lethal influx of protons, and deprived it of essential substrates (Figure 11). 
Macrophages are both the host cell for Leishmania replication and the effector cell for 
parasite killing. The parasite survives and persists in these late endosomes whose pH is 5 
- 5.5. Infection of macrophages does not trigger a pro-inflammatory response, and 
parasite carrying macrophages inhibit both apoptosis and necrosis[61-64]. The non-toxic 
delivery of AmB to these macrophage endosomes enables parasite killing by 
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apoptosis[65]. This can be enhanced by co-administration of recombinant IFN-γ or an 
anti-IL-10 receptor antibody[15,66]. It means that leishmania antigen needs to be:- (i) 
supplemented with TNF-α: (ii) iNOS has to be induced [67]; and (iii) IL-10 has to be 
neutralized in order to activate tissue macrophages to produce INF-γ[16]. Our results 
show that AmB-PMA treatment of CL lesions led to the rapid killing of parasites in 
macrophages, and to increased TNF-α, IFN-γ and iNOS in the lesion itself (Figures 9, 10 
& 11).  
 
Lecoeur et al. has recently shown that two key endpoints should be expected of any new 
treatment for CL[68].  The first is accelerated clearance of the maximal number of 
parasites. The second is rapid and stable tissue repair and regeneration. Parasites needed 
to be exposed to drug for 5 or more days to ensure the long term control of parasite load. 
This was because duration of parasite drug exposure was a stronger determinant of a 
good long term outcome than total drug dose.  Discontinuous drug applications were also 
better than several daily applications over a few days. The further clinical development of 
AmB-PMA as a potential pharmaceutical drug would benefit from the recent description 
of a transdermal delivery patch that consists of 600 µm long dissolving microneedles. 
This minimally invasive alternative to hypodermic injection would enable the simple and 
painless self-administration of AmB-PMA. Furthermore, there is no medical waste 
because the patch’s backing is made of a water soluble polymer that dissolves in a bowl 
of water that can simply be flushed away[69-71]. 
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5. Conclusion:
We report the chemical synthesis of a new water soluble non-toxic AmB-PMA that is 
chemically simple to make and is also stable during long term storage.  Administration by 
fine needle intradermal injection into CL lesions led to the rapid healing of both early and 
established L. major infections in the non-healing BALB/c mouse model of CL. A one 
week course of 3 injections was sufficient to achieve rapid healing and cure. The 
pharmacologically mediated activity of AmB was enhanced by host immune responses 
that accelerated healing and led to cure of the infection. This cost-effective AmB-PMA 
molecule has the potential to be developed into a suitable (and potentially self-
administered) transdermally delivered treatment for CL lesions for use in low income 
countries with limited healthcare resources. 
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Captions: 
Figure 1a: 
UV spectra 
UV spectra (300 to 450 nm) of AmB-PMA in water (solid line) as compared to deoxycholate-AmB 
[Fungizone, Squibb] (dotted line) and liposomal AmB [AmBisome, Gilead] (dashed line) at a concentration of 
10 µg of AmB/ml (n = 20). 
Figure 1b: 
pH related solubility 
pH related solubility of the AmB-PMA in water. AmB-PMA was dissolved in water for injection (pH 7.3) at 1 
mg of AmB/ml. On centrifugation, the AmB-PMA remained in solution. The solution pH was then adjusted to 
5. The clear solution went turbid and, when centrifuged at 1,800 rpm for 10 min, gave an orange-yellow
precipitate. The orange-yellow pellet dissolved in DMSO thereby confirming that it was free AmB. The 
optical density of the supernatants was measured at 409 nm and the result expressed as the percentage 
water solubility of the AmB in AmB-PMA when the solubility at pH 7.3 was 100% (n = 6). 
Figure 2:  
Erythrocyte lysis 
Erythrocyte lysis for AmB-PMA (▲) compared to deoxycholate-AmB (○), and liposomal AmB (□). (n = 20). 
PMA did not cause erythrocyte lysis.  
Figure 3: 
In vitro anti-leishmanial activity 
Anti-leishmanial activity of AmB-PMA (▲; ED50 = 0.07 ± 0.1 µg of AmB/ml) as compared to deoxycholate 
AmB (○; ED50 = 0.22 ± 0.1 µg AmB/ml) and liposomal AmB (□; ED50 = 0.11 ± 0.1 µg AmB/ml) in L. donovani 
amastigote infected macrophages (n = 9). PMA had no anti-leishmanial activity.  
Figure 4: 
In vitro immuno-modulatory activity 
TNF-α and IFN-γ mRNA as determined by quantitative real-time RT-PCR in macrophages treated with AmB-
PMA (50 µg of AmB/ml) and compared to deoxycholate-AmB  and liposomal AmB. Control cells were 
cultured in media only. Ultrapure Salmonella minnesota lipopolysaccharide (LPS) was used at 25 ng/ml. 
Endotoxin free PMA was used at 2 mg/ml and had no immuno-modulatory activity (n = 6). 
Figure 5a: 
In vivo anti-leishmanial activity – acute model 
In vivo activity of AmB-PMA in the acute non healing cutaneous lesion model in BALB/c mice infected with L. 
major promastigotes. Three intradermal injections were given over a 3 week period on days 7, 14 and 21 
post infection making a total dose of 400 µg of AmB/mouse (i.e., 18 mg of AmB/kg body weight). The 
footpad lesion size for AmB-PMA treated (□; open square; n = 24 mice/time point) and control (▲; closed 
triangle; n = 6 mice/time point) animals is shown. PMA had no anti-leishmanial activity. Grey shading on X-
axis:- time period during which 3 intradermal injections of AmB-PMA were given. 
Figure 5b: 
In vivo anti-leishmanial activity – established model 
In vivo activity of AmB-PMA in the established non healing cutaneous lesion model in BALB/c mice infected 
with L. major promastigotes. The presence of an established lesion was first confirmed by harvesting 4 
control mice for parasite load quantification and histological studies. A shortened treatment course was 
given; 3 intradermal injections over a one week period on days 21, 25 and 28 post infection making a total 
dose of 400 µg of AmB/mouse (i.e., 18 mg of AmB/kg body weight). The footpad lesion size for AmB-PMA 
treated (□; open square; n = 16 mice/time point) and control (▲; closed triangle; n = 6 mice/time point) 
animals is shown. PMA had no anti-leishmanial activity. Grey shading on the X-axis:- time period during 
which 3 intradermal injections of AmB-PMA were given. 
Figure 6: 
L. major parasite load in footpad lesions 
L. major parasite load by ex-vivo counting for AmB-PMA treated (□; open square) and control (▲; closed 
triangle) BALB/c mice in the acute lesion model (n = 6 mice/time point). The ○ symbol at day 0 is the 
infectious inoculum of L. major promastigotes used. 
Figure 7: 
Rechallenge experiment 
Challenge with parasites of BALB/c mice with a healed primary lesion by day 35 compared to mice with an 
unhealed primary infection at day 50. These mice were challenged with 2 x 10
6
 stationary phase L. major
promastigotes in the contralateral footpad on day 60. A classical delayed type hypersensitivity response was 
only seen in the footpads of the mice with AmB-PMA healed lesions (▄; closed square, mice with an AmB-
PMA healed lesion by day 35; ○; mice with an unhealed primary infection at day 50).(n = 12 mice/time 
point).  
Figure 8: 
Footpad histology 
Histological sections (H&E stain, x 1,000 magnification) showing the L. major footpad lesion in an infected 
and untreated BALB/c mouse footpad biopsy as compared to an infected and AmB-PMA treated (400 µg of 
AmB/mouse) BALB/c mouse footpad biopsy. (a) Infected and untreated at day 14. L. major amastigotes are 
seen in macrophages. (b) Infected and untreated at day 28. Numerous amastigotes are seen in the 
phagolysosomes of macrophages. (c) Infected and untreated at day 50. Numerous amastigotes persist in 
macrophage phagolysosomes. (d) Infected and treated at day 28. Neutrophils are present. There are no 
amastigotes. (e) Infected and treated at day 50. There are no neutrophils or amastigotes present. The lesion 
shows an infiltrate of histiocytes, lymphoid cells and plasma cells. (f) Infected and treated at day 80. The 
presence of myofibroblasts indicates that lesion healing is in its final stages. There are no amastigotes.  
Figures 9 a - d: 
Cytokine and chemokine responses - 1  
Quantitative real-time mRNA RT-PCR for TNF-α, IFN-γ, IL-10 and MIP-1β in BALB/c mice. AmB-PMA 
treated footpad (□; open square, solid line); control footpad (▲; closed triangle, dashed line); AmB-PMA 
treated (and normal size) draining lymph node (○; open circle, solid line); untreated (and enlarged) draining 
lymph node (●; closed circle, dashed line); Cytokine/chemokine in normal BALB/c mouse spleen (+; S) and 
lymph node (x; L). n = 6 mice/time point. 
Figure 10: 
Cytokine and chemokine responses - 2  
Quantitative real time mRNA RT-PCR for iNOS in BALB/c mice. AmB-PMA treated footpad (□; open square, 
solid line); control footpad (▲; closed triangle, dashed line); AmB-PMA treated (and normal size) draining 
lymph node (○; open circle, solid line); control (and enlarged) draining lymph node (●; closed circle); iNOS in 
normal BALB/c mouse lymph node (x; L). n = 6 mice/time point. 
Figure 11: 
Proposed mechanism of action 
The macrophage is the host cell for Leishmania replication and also the effector for parasite killing. The 
parasite survives and persists in the late endosomes whose pH is 5 - 5.5. Infection of macrophages does not 
trigger inflammation and parasite carrying macrophages are not activated. AmB-PMA accumulates in 
endosomes with a pH of 5 - 5.5. The change from physiological pH (7.3) to that of the endosomal lysosomal 
compartment pH (5 - 5.5) results in the collapse of the PMA hydrogel matrix. This leads to the release of free 
AmB. This endosomal AmB rapidly kills parasites, a process that is accelerated by the production of TNF-α, 
IFN-γ and iNOS within the CL lesion itself. 
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Supplementary Figure 1 
Stability studies of the AmB-PMA after storage as a lyophilised powder: 
Following synthesis, the lyophilised AmB-PMA molecule was reconstituted at 1 mg/ml 
AmB. It was found to have an AmB loading of 31 ± 2 %. It was then sealed under argon (i.e., 
oxygen and moisture free), covered in aluminium foil (i.e., protected from light) and stored at 
4°C for 17 days. It was found to have a loading of 30 ± 2 % AmB with a UV spectrum that 
was identical to the spectrum on day 1. It was also sealed under argon and stored in the dark 
at 4°C for 9 months. It was found to have a loading of 28 ± 2 % AmB. Its UV spectrum is 
shown below as compared to its UV spectrum on day 1. 
Conclusion: 
Neither the percentage loading of AmB nor the UV spectrum of AmB-PMA changed 
significantly after 9 month’s storage under argon and in the dark at 4°C. The AmB-PMA also 
retained its pH responsiveness as described in Figure 1b of the paper. 
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Supplementary Figure 2 
Macroscopic appearance of L. major footpad lesions 
Figure 2 a: 
L. major footpad lesion in an infected and untreated BALB/c mouse footpad at day 35. 
Figure 2b: L. major footpad lesion in an infected, treated and healed AmB-PMA treated 
BALB/c mouse footpad at day 80. 
